Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses

Clicks: 241
ID: 273286
2009
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Combination therapy with peginterferon alfa-2a and ribavirin is equally effective in patients with HCV monoinfection and in those with dual chronic HCV/HBV infection.
Reference Key
cj2009gastroenterologypeginterferon Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Liu CJ;Chuang WL;Lee CM;Yu ML;Lu SN;Wu SS;Liao LY;Chen CL;Kuo HT;Chao YC;Tung SY;Yang SS;Kao JH;Liu CH;Su WW;Lin CL;Jeng YM;Chen PJ;Chen DS;;
Journal gastroenterology
Year 2009
DOI DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/19084016
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male middle aged Comparative Study Antibodies Multicenter Study DNA viral / blood controlled clinical trial drug therapy combination dose-response relationship drug antiviral agents / therapeutic use* ribavirin / therapeutic use* taiwan hepatitis b / immunology recombinant proteins viral load hepacivirus / immunology hepatitis c / immunology antiviral agents / adverse effects interferon alpha-2 interferon-alpha / adverse effects interferon-alpha / therapeutic use* polyethylene glycols / adverse effects polyethylene glycols / therapeutic use* ribavirin / adverse effects hepatitis c / complications* hepatitis c / drug therapy* pmid:19084016 doi:10.1053/j.gastro.2008.10.049 chun-jen liu wan-long chuang ding-shinn chen hepatitis b / complications* hepatitis b / drug therapy* hepatitis b virus / immunology viral interference / physiology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.